Gold Standard
Regenerative
Emerging regenerative treatments that help protect nerve tissue, reduce brain inflammation, and support functional recovery in patients with neurological conditions.
Neurological conditions are among the most serious and growing challenges in modern medicine. From Parkinson's disease and multiple sclerosis to stroke recovery and nerve damage, these conditions share common root mechanisms: brain inflammation, damage to the protective coating around nerves, progressive nerve loss, and permanent loss of function. The impact on mobility, thinking, and quality of life can be severe. Many patients continue to decline despite the best available care.
Conventional treatments like disease-modifying drugs for MS, dopamine medications for Parkinson's, and rehabilitation for stroke are mainly designed to slow progression or manage symptoms. They do not address the underlying neuroinflammation that keeps driving nerve damage. They also do not meaningfully support the nervous system's own repair pathways. Many patients eventually hit a ceiling with medications while continuing to decline.
Regenerative medicine, especially mesenchymal stem cell (MSC) therapy, is being studied as a different approach. Researchers are investigating whether MSCs may release growth factors and influence inflammatory signals in the nervous system. This research is preliminary, these mechanisms are not established, and it is an actively developing area. Outcomes vary by condition, stage, and patient factors, these therapies are not FDA-approved, and no claims of cure or disease reversal are made.
Regenerative protocols for these neurological conditions are investigational and are areas of ongoing research. They are not FDA-approved, and any approach is determined by the treating physician.
Researchers are studying whether MSC-derived growth factors might support the brain's natural repair processes after a stroke. This use is investigational, the evidence is preliminary, and benefits are not established.
MS is an inflammatory condition where the immune system attacks the protective coating around nerve fibers. Researchers are studying whether MSC-based approaches might influence inflammatory activity in MS. These protocols are investigational, not FDA-approved, and benefits are not established.
Parkinsonian syndromes involve the loss of dopamine-producing nerve cells and progressive motor decline. This is an early and emerging area of research. Some small studies have explored whether signals from MSCs might affect disease processes, but the evidence is preliminary, benefits are not established, and these therapies are not FDA-approved for Parkinson's or related conditions.
Peripheral neuropathy from diabetes, chemotherapy, or injury can cause pain, numbness, and weakness. Researchers are studying whether MSC-derived exosomes might support nerve repair. This use is investigational and benefits are not established.
A personalized protocol built through a thorough neurological assessment, imaging review, and collaborative planning with the independent clinical team.
We review available imaging of the brain and spinal cord, validated scoring tools for your specific condition, medication history, and your full disease timeline. This baseline establishes your current function and helps identify the most appropriate regenerative approach for your diagnosis and stage.
Based on your assessment, we select the right delivery method. IV infusion is used for systemic conditions like MS. More targeted delivery routes are used for conditions requiring direct access to the nervous system. The method is chosen based on your condition, disease stage, and physician judgment.
All procedures are outpatient. Standard IV infusions take 2 to 4 hours. More targeted delivery methods are performed in a licensed clinical setting with appropriate monitoring. All cell preparations come from rigorously screened, certified providers.
We re-evaluate your condition at 6 to 12 weeks after treatment using validated neurological assessment tools. Repeat imaging or functional testing is ordered as needed. Our team coordinates with your existing neurologist throughout the monitoring period.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifyNeurological response to regenerative therapy develops gradually. This timeline reflects patterns observed in clinical experience and research. Individual outcomes vary by condition, stage, and patient factors.
Any changes are assessed by the treating physician. Some patients report changes in how they feel, but individual responses vary and no specific outcome is guaranteed.
Growth factors support the nerve tissue environment. Subtle improvements in motor function, thinking, or sensation may begin to emerge depending on the condition being treated.
Patients who respond well typically notice measurable improvements in function, mobility, or symptoms during this phase. We use validated scoring tools to objectively track these changes from baseline.
The independent clinical team evaluates treatment response using validated neurological assessments. Additional sessions are considered based on individual outcomes, disease trajectory, and physician recommendation.
Peripheral neuropathy, nerve inflammation, and support following certain neurological injuries are the areas most often asked about. Evidence in neurological conditions is generally earlier and weaker than in joint conditions.
No. These therapies are not approved by the U.S. Food and Drug Administration for any neurological disease. Any suggestion that a regenerative protocol treats a progressive neurological condition goes well beyond what the evidence supports.
Delivery route depends on the protocol and is one of the things a physician determines. It is also one of the areas where the science is least settled, and honest discussion of it should acknowledge that.
Neurological applications remain investigational. Published work is largely early-stage, and effect sizes and durability are not established. Anyone considering this should weigh that carefully.
Advanced or rapidly progressing disease, certain uncontrolled medical conditions, and cases where the underlying diagnosis is unclear. A physician makes that assessment after reviewing your records.
Connect with our coordination team to explore whether regenerative therapy may be available for your neurological condition and goals through an independent provider.
CHECK IF YOU QUALIFY →Medically reviewed by Dr. Karla Chavira, MD, Regenerative Medicine Physician and CEO of CMCells (Cédula Profesional on file).
Last reviewed: July 2026